Stuart J Schnitt

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines
    Patrica J Keller
    Department of Anatomy and Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, MA 02111, USA
    Breast Cancer Res 12:R87. 2010
  2. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
  3. pmc Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting
    Laurel A Habel
    Division of Research, Kaiser Permanente, Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Breast Cancer Res 11:R85. 2009
  4. pmc The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Breast Cancer Res 5:263-8. 2003
  5. doi request reprint Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Mod Pathol 23:S60-4. 2010
  6. doi request reprint Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst Monogr 2010:158-61. 2010
  7. ncbi request reprint Benign breast disease and breast cancer risk: morphology and beyond
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Surg Pathol 27:836-41. 2003
  8. pmc The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 11:101. 2009
  9. ncbi request reprint Clinging carcinoma: an American perspective
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Semin Diagn Pathol 27:31-6. 2010
  10. pmc Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk
    Ying Liu
    Affiliations of authors Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO YL, GAC Alvin J Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, St Louis, MO GAC Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA BR, CSB, WYC, RMT Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA LCC, SJS, JLC Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA WCW
    J Natl Cancer Inst 105:1571-8. 2013

Detail Information

Publications89

  1. pmc Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines
    Patrica J Keller
    Department of Anatomy and Cellular Biology, Sackler School, Tufts University School of Medicine, Boston, MA 02111, USA
    Breast Cancer Res 12:R87. 2010
    ..While cultured cell lines have been derived from both normal and malignant tissues, it remains unclear whether they retain a similar cellular heterogeneity as to that found within breast tissues...
  2. pmc Breast cancer prognostic classification in the molecular era: the role of histological grade
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK
    Breast Cancer Res 12:207. 2010
    ....
  3. pmc Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting
    Laurel A Habel
    Division of Research, Kaiser Permanente, Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Breast Cancer Res 11:R85. 2009
    ..The aims of this study were to examine the use and impact of these therapies on risk of recurrence among ductal carcinoma in situ patients diagnosed and treated in the community setting...
  4. pmc The diagnosis and management of pre-invasive breast disease: flat epithelial atypia--classification, pathologic features and clinical significance
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Breast Cancer Res 5:263-8. 2003
    ..Additional studies are needed to better understand the biological nature and clinical significance of these lesions...
  5. doi request reprint Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Mod Pathol 23:S60-4. 2010
    ....
  6. doi request reprint Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst Monogr 2010:158-61. 2010
    ....
  7. ncbi request reprint Benign breast disease and breast cancer risk: morphology and beyond
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Surg Pathol 27:836-41. 2003
    ..Additional information derived from clinicopathologic follow-up studies, epidemiologic studies, and molecular and genetic studies will provide new insights into benign breast disease and breast cancer risk...
  8. pmc The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 11:101. 2009
    ..The potential roles of myoepithelial cells and of stromal-epithelial interaction are of particular interest in this regard...
  9. ncbi request reprint Clinging carcinoma: an American perspective
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Semin Diagn Pathol 27:31-6. 2010
    ....
  10. pmc Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk
    Ying Liu
    Affiliations of authors Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO YL, GAC Alvin J Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, St Louis, MO GAC Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA BR, CSB, WYC, RMT Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA LCC, SJS, JLC Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA WCW
    J Natl Cancer Inst 105:1571-8. 2013
    ..No study has characterized the contribution of alcohol consumption during this interval to risks of proliferative benign breast disease (BBD) and breast cancer...
  11. ncbi request reprint The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer 107:1240-7. 2006
    ..However, the influence of a positive family history (FH) on breast cancer risk among women with biopsy-confirmed BBD is less certain...
  12. pmc Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue Boston, MA 02215, USA
    Am J Surg Pathol 33:1802-8. 2009
    ..Whether these features contribute to the higher local recurrence risk in young women with DCIS treated with the breast-conserving therapy requires further study...
  13. pmc Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease
    Xuefen Su
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, 3rd Floor, Boston, MA 02115, USA
    Cancer Causes Control 21:1033-46. 2010
    ..We examined the association between adolescent fiber intake and proliferative BBD, a marker of increased breast cancer risk, in the Nurses' Health Study II...
  14. pmc Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS
    Larissa Nekhlyudov
    Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 133 Brookline Ave, 6th Floor, Boston, MA 02215, USA
    J Natl Cancer Inst 104:614-21. 2012
    ..Breast-conserving surgery (BCS) is the most common treatment for ductal carcinoma in situ (DCIS); however, how often women experience subsequent diagnostic evaluations over time is not known...
  15. pmc Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies
    Heather J Baer
    Division of General Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Cancer 115:1404-11. 2009
    ..Lobules in normal breast tissue can be classified based on their degree of development, which may affect their susceptibility to carcinogenesis. However, few epidemiologic studies to date have addressed this...
  16. pmc Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer
    Rulla M Tamimi
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Breast Cancer Res Treat 128:243-50. 2011
    ..Further studies to confirm these findings are necessary...
  17. pmc Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics
    Sibgat Choudhury
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cell Stem Cell 13:117-30. 2013
    ..Our results suggest that pathways controlling p27(+) mammary epithelial cells and the numbers of these cells relate to breast cancer risk and can be explored for cancer risk assessment and prevention. ..
  18. pmc Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer
    Rulla M Tamimi
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Breast Cancer Res Treat 131:159-67. 2012
    ..Identifying risk factors for less common subtypes such as luminal B, HER2-type and basal-like tumors has important implications for prevention of these more aggressive subtypes...
  19. pmc Columnar cell lesions and subsequent breast cancer risk: a nested case-control study
    Sarah A Aroner
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Breast Cancer Res 12:R61. 2010
    ..However, the risk of subsequent breast cancer associated with the presence of CCL in a benign breast biopsy is poorly understood...
  20. doi request reprint Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Breast Cancer Res Treat 139:453-60. 2013
    ..Future research efforts should focus on non-clinicopathologic factors to identify more powerful risk factors for LR...
  21. doi request reprint Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers
    Jennifer S Kaplan
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am J Surg Pathol 36:1483-8. 2012
    ..We conclude that ER+ BRCA1-related breast cancers show several morphologic and immunophenotypic differences from ER+ sporadic breast cancers as well as some similarities to ER- BRCA1-related cancers...
  22. pmc High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:18378-83. 2011
    ..The findings indicate that HSF1 should be evaluated prospectively as an independent prognostic indicator in ER-positive breast cancer. HSF1 may ultimately be a useful therapeutic target in cancer...
  23. pmc Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer
    Rulla M Tamimi
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA, 02115, USA
    Breast Cancer Res 10:R67. 2008
    ..The purpose of this study was to compare the prevalence of these distinct molecular subtypes among cases of DCIS and invasive breast cancer...
  24. pmc COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin
    Michelle D Holmes
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Breast Cancer Res Treat 130:657-62. 2011
    ..The survival benefit associated with aspirin use did not differ by COX-2 status. COX-2 breast cancer expression is associated with worse prognosis. If aspirin truly impacts breast cancer survival, then it is not solely via COX-2...
  25. ncbi request reprint Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer 109:180-7. 2007
    ..Atypical hyperplasia (AH) in a benign breast biopsy is associated with an increased breast cancer risk. However, the influence of the histologic type of AH on the magnitude and laterality of breast cancer risk is poorly defined...
  26. doi request reprint Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Am J Surg Pathol 33:1093-7. 2009
    ..However, whether or not expression of biomarkers characteristic of basal-like breast cancers helps to define a subset of women with triple-negative breast cancers who are likely to harbor BRCA1 mutations is an unresolved issue...
  27. pmc Androgen receptor expression and breast cancer survival in postmenopausal women
    Rong Hu
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 17:1867-74. 2011
    ..However, the association between tumor AR status and breast cancer survival is uncertain. Hence, we examined the association between AR status and breast cancer survival in the Nurses' Health Study (NHS)...
  28. pmc Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies
    Sarah A Aroner
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    Breast Cancer Res Treat 139:277-85. 2013
    ..Larger studies are needed to further evaluate whether risk is increased when multiple RS are present and whether associations vary by age at biopsy or by hormone receptor status of the breast tumor...
  29. pmc Benign breast disease, recent alcohol consumption, and risk of breast cancer: a nested case-control study
    Rulla M Tamimi
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Breast Cancer Res 7:R555-62. 2005
    ....
  30. pmc Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery
    Larissa Nekhlyudov
    Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, 133 Brookline Ave, 6th Floor, Boston, MA 02215, USA
    J Clin Oncol 27:3211-6. 2009
    ..CONCLUSION Surveillance mammography after BCS among insured women with DCIS often did not occur yearly and declined over time after treatment. Patients and providers must remain vigilant about surveillance after BCS...
  31. ncbi request reprint Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer 103:1778-84. 2005
    ..Studies of patients with ductal carcinoma in situ (DCIS) "treated" by diagnostic biopsy alone have been rare, but provide important opportunities to gain insights into the natural history of these lesions...
  32. ncbi request reprint A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer
    May Lim
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 65:1149-54. 2006
    ..Whether a subset of women can achieve local control without RT is unknown. In 1986, we initiated a prospective one-arm trial of BCS alone for highly selected breast-cancer patients. This report updates those results...
  33. pmc Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease
    Xuefen Su
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 126:180-90. 2010
    ..These results suggest that genetic variants and circulating levels of IGFBP-3 may play a role in the early stage of breast carcinogenesis...
  34. ncbi request reprint Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)
    Julia S Wong
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Breast Cancer Res Treat 143:343-50. 2014
    ..This information should be useful as patients and clinicians weigh the options of wide excision with and without radiation. ..
  35. pmc Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
    ....
  36. pmc Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Appl Immunohistochem Mol Morphol 17:438-41. 2009
    ..Whether or not TMAs may also be a potentially useful platform for assessing biomarkers in benign proliferative breast lesions (BPBL) and normal breast tissue has not been previously studied in detail...
  37. pmc Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression
    Celina G Kleer
    Department of Pathology, University of Michigan Cancer Center, Ann Arbor, Michigan, USA
    Clin Cancer Res 14:5357-67. 2008
    ..To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression...
  38. pmc Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 12:R12. 2010
    ..We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors...
  39. pmc Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
    Larissa J Lee
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 117:3093-100. 2011
    ..The clinical outcome of women with and without BRCA1 mutations who had TN breast cancer treated with conventional chemotherapy were compared...
  40. pmc Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Mod Pathol 24:924-31. 2011
    ..Our findings raise the possibility that targeting the androgen receptor pathway may represent a novel therapeutic approach to the management of patients with basal-like cancers...
  41. doi request reprint Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications
    Justin B Hilson
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Am J Surg Pathol 33:227-32. 2009
    ..This observation should be taken into consideration when selecting MEC markers to help distinguish in situ from invasive breast carcinomas...
  42. ncbi request reprint Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast
    Justin B Hilson
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 34:896-900. 2010
    ..This needs to be taken into consideration when selecting myoepithelial markers to help distinguish benign sclerosing lesions from invasive breast cancer...
  43. doi request reprint DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer
    Brian M Alexander
    Dana Farber Brigham and Women s Cancer Center Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 16:5796-804. 2010
    ....
  44. doi request reprint Thyroid transcription factor-1 expression in breast carcinomas
    Judith Robens
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 34:1881-5. 2010
    ..We conclude that a small proportion of breast carcinomas show TTF-1 expression. Therefore, the presence of TTF-1 immunoreactivity in a carcinoma cannot by itself be used to exclude the possibility of a breast origin...
  45. doi request reprint Evolution of breast-conserving therapy for localized breast cancer
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:1395-6. 2008
  46. ncbi request reprint Columnar cell lesions of the breast
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, U S A
    Adv Anat Pathol 10:113-24. 2003
    ..Recent studies have begun to provide insights into the biological nature and clinical significance of these lesions. In this article, we review the current state of knowledge and propose a simplified scheme for their classification...
  47. ncbi request reprint Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer
    Bradley B Bryan
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Mod Pathol 19:617-21. 2006
    ....
  48. doi request reprint Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?
    Rinaa S Punglia
    Affiliations of authors Department of Radiation Oncology RSP and Division of Medical Oncology JCW, Dana Farber Cancer Institute, Boston, MA Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA SJS
    J Natl Cancer Inst 105:1527-33. 2013
    ....
  49. ncbi request reprint Early life factors and incidence of proliferative benign breast disease
    Heather J Baer
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:2889-97. 2005
    ..These results indicate that premenopausal women who were heavier at young ages have lower incidence of proliferative benign breast disease, consistent with previous findings for breast cancer...
  50. ncbi request reprint p63 Immunocytochemistry improves accuracy of diagnosis with fine-needle aspiration of the breast
    Anthony M Harton
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Clin Pathol 128:80-5. 2007
    ..When used in conjunction with morphologic examination, p63 immunostaining may be useful to categorize cases problematic by Papanicolaou staining...
  51. ncbi request reprint Prospective study of wide excision alone for ductal carcinoma in situ of the breast
    Julia S Wong
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1031-6. 2006
    ..It has been hypothesized that wide excision alone with margins > or = 1 cm may be adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS). To test this hypothesis, we conducted a prospective, single-arm trial...
  52. ncbi request reprint Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Surg Pathol 30:1002-7. 2006
    ....
  53. ncbi request reprint Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer
    Meena S Moran
    Meena S Moran, Yale University School of Medicine, New Haven, CT Stuart J Schnitt and Jay R Harris, Harvard Medical School, Boston, MA Armando E Giuliano, Cedars Sinai Medical Center, Los Angeles, CA Seema A Khan, Northwestern University Feinberg School of Medicine, Chicago, IL Janet Horton, Duke University Medical Center, Durham, NC Suzanne Klimberg, University of Arkansas for Medical Sciences, Fayetteville, AR Mariana Chavez MacGregor, University of Texas MD Anderson Cancer Center, Houston, TX Gary Freedman, University of Pennsylvania School of Medicine, Philadelphia, PA Nehmat Houssami, School of Public Health, University of Sydney Medical School, Sydney, New South Wales, Australia Peggy L Johnson, Susan G Komen Advocate in Science, Wichita, KS and Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:1507-15. 2014
    ..Controversy exists regarding the optimal margin width in breast-conserving surgery for invasive breast cancer...
  54. ncbi request reprint Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers
    Nadine Tung
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 146:175-82. 2014
    ..Carriers who underwent oophorectomy had a significantly lower rate of breast cancer-related death; this finding should be studied further in all women with TNBC. ..
  55. pmc Significance analysis of prognostic signatures
    Andrew H Beck
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Comput Biol 9:e1002875. 2013
    ..SAPS is a powerful new method for deriving robust prognostic biological signatures from clinically annotated genomic datasets...
  56. pmc Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast
    Yunn Yi Chen
    Department of Pathology, University of California San Francisco, California 94143, USA
    Am J Surg Pathol 33:1683-94. 2009
    ..However, clinical follow-up studies will be required to define the natural history and most appropriate management of these lesions...
  57. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  58. ncbi request reprint Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Mod Pathol 20:1149-55. 2007
    ....
  59. doi request reprint Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training
    Roderick R Turner
    Department of Pathology, Saint John s Health Center, 1328 Twenty Second St, Santa Monica, CA 90404, USA
    J Clin Oncol 26:258-63. 2008
    ..We sought to determine whether a set of clearly defined histologic criteria could lead to reproducible nodal classification by pathologists...
  60. ncbi request reprint HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Mod Pathol 18:615-20. 2005
    ..Whether or not HER2 overexpression is associated with a diminished response to tamoxifen in patients with ER-positive DCIS will require investigation in clinical outcome studies...
  61. pmc Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics
    Lusine Yaghjyan
    Department of Surgery, Division of Public Health Sciences, Washington University in St Louis School of Medicine, St Louis, MO, USA
    J Natl Cancer Inst 103:1179-89. 2011
    ..We aimed to determine whether the associations between breast density and subsequent breast cancer varied by tumor characteristics...
  62. ncbi request reprint Alcohol consumption and incidence of benign breast disease
    Celia Byrne
    Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 11:1369-74. 2002
    ..However, greater alcohol consumption earlier in life (ages 18-22 years) was associated with higher proliferative BBD rates, suggesting that timing of exposure may be relevant to disease incidence...
  63. doi request reprint Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry
    David J Dabbs
    Department of Pathology, Magee Women s Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Am J Surg Pathol 37:e1-11. 2013
    ..This review provides an update on recent clinicopathologic and molecular data on LN and invasive lobular carcinoma and a discussion about the use and limitations of IHC with E-cadherin in diagnostic breast pathology...
  64. ncbi request reprint Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Am J Clin Pathol 123:16-20. 2005
    ..The overwhelming majority of breast cancers are either completely ER- or unambiguously ER+, and cases with weak ER immunostaining are rare...
  65. ncbi request reprint Adolescent diet and incidence of proliferative benign breast disease
    Heather J Baer
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 12:1159-67. 2003
    ..05). Vegetable fat, vitamin E, and fiber intakes during adolescence were inversely associated with risk of proliferative BBD in this population. Confirmation of these associations may suggest a means for prevention of breast cancer...
  66. ncbi request reprint Nonmalignant lesions in breast core needle biopsies: to excise or not to excise?
    Timothy W Jacobs
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Surg Pathol 26:1095-110. 2002
    ..These include atypical ductal hyperplasia, lobular neoplasia (atypical lobular hyperplasia and lobular carcinoma in situ), papillary lesions, radial scars, fibroepithelial lesions, mucocele-like lesions, and columnar cell lesions...
  67. ncbi request reprint Estrogen receptor testing of breast cancer in current clinical practice: what's the question?
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 24:1797-9. 2006
  68. ncbi request reprint Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial
    Laura C Collins
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Surg Pathol 28:126-31. 2004
    ....
  69. ncbi request reprint Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop
    Ann H Partridge
    Department of Medicine, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02215, USA
    CA Cancer J Clin 62:203-10. 2012
    ....
  70. ncbi request reprint Images in pathology. Conversation between needle biopsies
    Stuart J Schnitt
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Int J Surg Pathol 11:117. 2003
  71. ncbi request reprint Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma
    Sarah A Thurman
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 59:152-9. 2004
    ..To evaluate the site of first failure of patients with early-stage tubular, mucinous, and medullary breast carcinoma after breast-conserving therapy and compare their results with those of patients with infiltrating ductal carcinoma (IDC)...
  72. ncbi request reprint Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma
    Wendy Y Chen
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 101:1490-500. 2004
    ....
  73. ncbi request reprint Molecular definition of breast tumor heterogeneity
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 11:259-73. 2007
    ..Our data suggest prognostic relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations...
  74. ncbi request reprint A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion
    Michael Overholtzer
    Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
    Cell 131:966-79. 2007
    ....
  75. ncbi request reprint Radial scars of the breast and breast carcinomas have similar alterations in expression of factors involved in vascular stroma formation
    Timothy W Jacobs
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hum Pathol 33:29-38. 2002
    ..These results suggest that a similar disturbance in stromal-epithelial interactions is present in both lesions...
  76. ncbi request reprint HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
    J Clin Oncol 22:854-63. 2004
    ..Several tests of varying accuracy and cost are available to identify candidates for trastuzumab. We estimated the cost-effectiveness of alternative HER-2 testing and trastuzumab treatment strategies...
  77. ncbi request reprint Family history of breast cancer, age and benign breast disease
    Penelope M Webb
    Department of Social and Preventive Medicine, University of Queensland, Brisbane, Australia
    Int J Cancer 100:375-8. 2002
    ..This link adds weight to the belief that BBD with atypia is a precursor or marker lesion for breast cancer...
  78. ncbi request reprint Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast
    Frances P O'Malley
    Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mod Pathol 19:172-9. 2006
    ..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria...
  79. ncbi request reprint (99m)Tc sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study
    Iraj Khalkhali
    Harbor UCLA Medical Center, Torrance, CA, USA
    Radiology 222:149-55. 2002
    ..To evaluate the accuracy of scintimammography as an adjunct to physical examination and mammography in the detection of breast cancer in women with dense and fatty breasts...
  80. ncbi request reprint MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883
    Mitchell D Schnall
    Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Surg Oncol 92:32-8. 2005
    ..We report on the rate of MRI and mammography detection of foci of distinct incidental cancer in a prospective, multi center trial involving 426 women with confirmed breast cancer at 15 institutions in the US, Canada, and Germany...
  81. ncbi request reprint Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going?
    Stuart J Schnitt
    Am J Clin Pathol 120:485-8. 2003
  82. ncbi request reprint Screening women at high risk for breast cancer with mammography and magnetic resonance imaging
    Constance D Lehman
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109 1023, USA
    Cancer 103:1898-905. 2005
    ..The authors compared the performance of screening mammography versus magnetic resonance imaging (MRI) in women at genetically high risk for breast cancer...
  83. ncbi request reprint Magnetic resonance imaging of the breast prior to biopsy
    David A Bluemke
    Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    JAMA 292:2735-42. 2004
    ..Breast magnetic resonance imaging (MRI) has been shown to have high sensitivity for cancer detection and is increasingly used following mammography to evaluate suspicious breast lesions...
  84. ncbi request reprint A prospective study of diet and benign breast disease
    Penelope M Webb
    Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Australia
    Cancer Epidemiol Biomarkers Prev 13:1106-13. 2004
    ..They do, however, raise the possibility that high caffeine intake may increase, and use of vitamin supplements may decrease risk of developing AH...
  85. ncbi request reprint Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial
    Constance D Lehman
    Department of Radiology, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    J Surg Oncol 92:9-15; discussion 15-6. 2005
    ..To estimate the added cancer yield of magnetic resonance imaging (MRI) over mammography in the contralateral breast of patients with a recent diagnosis of breast cancer...
  86. ncbi request reprint Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
    Lyndsay N Harris
    Dana Farber Cancer Institute
    Clin Cancer Res 13:1198-207. 2007
    ....
  87. ncbi request reprint Standard for the management of ductal carcinoma in situ of the breast (DCIS)
    Monica Morrow
    Northwestern University Medical School, Chicago, IL, USA
    CA Cancer J Clin 52:256-76. 2002
    ....
  88. ncbi request reprint Diagnostic architectural and dynamic features at breast MR imaging: multicenter study
    Mitchell D Schnall
    Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
    Radiology 238:42-53. 2006
    ..To prospectively determine the prevalence and predictive value of three-dimensional (3D) and dynamic breast magnetic resonance (MR) imaging and contrast material kinetic features alone and as part of predictive diagnostic models...
  89. ncbi request reprint Standard for breast conservation therapy in the management of invasive breast carcinoma
    Monica Morrow
    Northwestern University Medical School, Chicago, IL, USA
    CA Cancer J Clin 52:277-300. 2002
    ....